Protagonist Therapeutics' financial profile is dominated by episodic milestone payments, as evidenced by revenue surging to $213.5M in 2026Q2 from $7.4M in 2025Q4, while R&D expenses have steadily climbed to $42.1M.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue is highly volatile, swinging from $255.0M in 2024Q1 to $4.2M in 2024Q2, with gross margins artificially at 100% due to zero COGS, while R&D expenses have grown 25.7% from $33.5M to $42.1M over the same period.
PTGX's proprietary peptide engineering platform has already demonstrated innovation and execution potential in biotech.
The company's clinical assets are seen as undervalued, offering significant upside potential.
PTGX's strategic optionality, including partnerships or licensing opportunities, adds to its bullish case.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | $3.07+22.8% vs $2.50 | $274M+15.1% vs $238M |
Q3 2026 Aug 5, 2026 | $2.29+2.7% vs $2.23 | $213M+7.5% vs $199M |
Q2 2026 May 5, 2026 | $0.05+107.7% vs -$0.65 | $56M+381.7% vs $12M |
Q1 2026 Feb 25, 2026 | -$0.69-30.2% vs -$0.53 | $7M-14.9% vs $9M |
Protagonist Therapeutics (PTGX) came out with quarterly earnings of $3.07 per share, beating the Zacks Consensus Estimate of $2.58 per share. This compares to a loss of $0.62 per share a year ago.
Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The mean of analysts' price targets for Protagonist Therapeutics (PTGX) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Benchmark PTGX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Protagonist Therapeutics, Inc. (PTGX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $132.04 | $8.49B | 27.67 | -89.41% | 62.04% | 42.83% | — | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — | |
| $131.73 | $10.84B | -37.73 | -16.72% | -341.87% | -22.39% | — | |
| $7.97 | $417.26M | -17.11 | -92.84% | -45.43% | -8.34% | — | |
| $3.90 | $544.69M | -7.32 | -58.19% | -1244.09% | -59.2% | — | |
| $2.88 | $711.44M | -12.98 | 22.09% | -11.85% | -35.3% | — |
Protagonist Therapeutics, Inc. (PTGX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Protagonist Therapeutics, Inc. (PTGX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Jun 18, 2026·SEC
May 5, 2026·SEC
Get notified when PTGX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Protagonist Therapeutics, Inc. (PTGX) stock FAQ — growth, dividends, profitability & financials explained
Protagonist Therapeutics, Inc. (PTGX) reported $551.7M in revenue over the trailing twelve months. Revenue was $46.0M in fiscal year 2025.
Protagonist Therapeutics, Inc. (PTGX) grew revenue by 163.7% over the trailing twelve months, compared with the twelve months before.
Yes. Protagonist Therapeutics, Inc. (PTGX) earned $342.3M in net income over the trailing twelve months (a 62.0% net margin).
Protagonist Therapeutics, Inc. (PTGX) had a return on equity (ROE) of 42.8% over the trailing twelve months. That is well above the market's typical 10-15%.
Protagonist Therapeutics, Inc. (PTGX) generated $110.7M in free cash flow over the trailing twelve months.
